AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30201050 — intervention group
Group type: EXPERIMENTAL
Intervention: Three‐dimensionally integrated exercise for scoliosis
Number of subjects: 42
Study 30201050 — intervention group
Group type: COMPARATOR
Intervention: Standard care of observation following the Scoliosis Research Society criteria
Number of subjects: 42
Study 28852716 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry cupping therapy on the abdominal wall for 8 minutes every other day for 4 weeks
Number of subjects: 120
Study 28852716 — intervention group
Group type: COMPARATOR
Intervention: Standard laxative therapy (Polyethylene glycol (PEG) 40% solution without electrolyte), 0.4 g/kg once daily for 4 weeks
Number of subjects: 120
Study 28852716 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry cupping therapy
Number of subjects: 120
Study 28852716 — intervention group
Group type: COMPARATOR
Intervention: Standard laxative therapy
Number of subjects: 120
Study 24614829 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremity progressive resistance exercises (PRE)
Number of subjects: 19
Study 24614829 — intervention group
Group type: COMPARATOR
Intervention: Endurance exercises (EE)
Number of subjects: 19
Study 23088650 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-rituximab
Number of subjects: 676
Study 23088650 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 676
Study 20202349 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized guidelines for reporting RCTs (REFLECT statement)
Number of subjects: 0
Study 20202349 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifications to the CONSORT statement for livestock trials
Number of subjects: 0
Study 17623805 — intervention group
Group type: EXPERIMENTAL
Intervention: meat-sweet dietary pattern (4th quartile)
Number of subjects: 2995
Study 17623805 — intervention group
Group type: EXPERIMENTAL
Intervention: meat-sweet dietary pattern (4th quartile) in postmenopausal women with estrogen receptor-positive tumors
Number of subjects: 2995
Study 17623805 — intervention group
Group type: EXPERIMENTAL
Intervention: vegetable-soy dietary pattern
Number of subjects: 2995
Study 17666216 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite (HDM) specific IL-5 responses at 3 years
Number of subjects: 370
Study 17666216 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite (HDM) specific IL-5 responses at 5 years
Number of subjects: 370
Study 17666216 — intervention group
Group type: EXPERIMENTAL
Intervention: Other HDM-specific cytokine responses
Number of subjects: 370
Study 17666216 — intervention group
Group type: COMPARATOR
Intervention: HDM avoidance intervention
Number of subjects: 370
Study 15066880 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous physical activity
Number of subjects: 878
Study 15066880 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level of vigorous physical activity
Number of subjects: 878
Study 15066880 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting behavioral guidelines for physical activity
Number of subjects: 878
Study 15066880 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior and dietary fiber guidelines
Number of subjects: 878
Study 15066880 — intervention group
Group type: EXPERIMENTAL
Intervention: Minority background (Hispanic or other)
Number of subjects: 878
Study 11413350 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive mechanical ventilation (NMV) for 1 year in volume cycled mode
Number of subjects: 33
Study 9250103 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea flavonoids (black tea)
Number of subjects: 14
Study 9250103 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea flavonoids (in vitro)
Number of subjects: 14
Study 9250103 — intervention group
Group type: EXPERIMENTAL
Intervention: Theaflavins (in vitro)
Number of subjects: 14
Study 9250103 — intervention group
Group type: COMPARATOR
Intervention: Control (no tea consumption)
Number of subjects: 14
Study 8513736 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution (1.5 mmols and above)
Number of subjects: 53
Study 3593627 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 0.2% (w/w) triclosan
Number of subjects: 12
Study 29458229 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Closure (PC)
Number of subjects: 38
Study 29458229 — intervention group
Group type: COMPARATOR
Intervention: Delayed Closure (DC)
Number of subjects: 38
Study 29458229 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PC and DC
Number of subjects: 38
Study 28810136 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 123
Study 28810136 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 123
Study 25916923 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation guided by lactate clearance rate (LC) and central venous oxygen saturation (ScvO₂)
Number of subjects: 100
Study 25916923 — intervention group
Group type: COMPARATOR
Intervention: Fluid resuscitation guided by central venous oxygen saturation (ScvO₂) alone
Number of subjects: 100
Study 23608794 — intervention group
Group type: EXPERIMENTAL
Intervention: Golden Bifid 2.0 g, bid for 24 months
Number of subjects: 60
Study 23608794 — intervention group
Group type: EXPERIMENTAL
Intervention: Changmei 1.0 g, tid for 24 months
Number of subjects: 60
Study 23608794 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Golden Bifid and Changmei for 24 months
Number of subjects: 60
Study 21340624 — intervention group
Group type: EXPERIMENTAL
Intervention: SCORE ≥ 5
Number of subjects: 163185
Study 21340624 — intervention group
Group type: EXPERIMENTAL
Intervention: SCORE ≥ 5 combined with HbA(1c) ≥ 6.0%
Number of subjects: 163185
Study 21340624 — intervention group
Group type: EXPERIMENTAL
Intervention: SCORE ≥ 5 combined with glucose measures
Number of subjects: 163185
Study 21340624 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose measures alone
Number of subjects: 163185
Study 21340624 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c) alone
Number of subjects: 163185
Study 19218299 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometry
Number of subjects: 74
Study 19218299 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures of physical activity
Number of subjects: 74
Study 17204901 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic-band method
Number of subjects: 38
Study 17204901 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal placement
Number of subjects: 38
Study 17204901 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastoid placement
Number of subjects: 38
Study 17204901 — intervention group
Group type: EXPERIMENTAL
Intervention: Forehead placement
Number of subjects: 38
Study 17204901 — intervention group
Group type: COMPARATOR
Intervention: Unoccluded condition
Number of subjects: 38
Study 17204901 — intervention group
Group type: EXPERIMENTAL
Intervention: Occluded condition
Number of subjects: 38
Study 15204011 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg xaliproden
Number of subjects: 54
Study 15204011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 12408777 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM (Arm A)
Number of subjects: 42
Study 12408777 — intervention group
Group type: COMPARATOR
Intervention: GEM + CDDP (Arm B)
Number of subjects: 42
Study 9824789 — intervention group
Group type: EXPERIMENTAL
Intervention: piperacillin (4 g) plus ciprofloxacin (400 mg)
Number of subjects: 12
Study 9824789 — intervention group
Group type: EXPERIMENTAL
Intervention: piperacillin (4 g) plus tazobactam (0.5 g)
Number of subjects: 12
Study 9824789 — intervention group
Group type: COMPARATOR
Intervention: piperacillin (4 g)
Number of subjects: 12
Study 9824789 — intervention group
Group type: COMPARATOR
Intervention: ciprofloxacin (400 mg)
Number of subjects: 12
Study 7815670 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminovenös‐N‐päd 10% (contains acetylated tyrosine and acetylated cysteine)
Number of subjects: 20
Study 7815670 — intervention group
Group type: COMPARATOR
Intervention: Vaminolact 6.5% (does not contain acetylated amino acids)
Number of subjects: 20
Study 7815670 — intervention group
Group type: COMPARATOR
Intervention: Primène 10% (does not contain acetylated amino acids)
Number of subjects: 20
Study 2529686 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrocoagulation (BE)
Number of subjects: 0
Study 2529686 — intervention group
Group type: COMPARATOR
Intervention: Endocoagulation (EK)
Number of subjects: 0
Study 31867673 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based delivery of a range of contraceptives
Number of subjects: 140
Study 28643315 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano carbon development combined with artery approach
Number of subjects: 70
Study 28643315 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 70
Study 25812179 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased oral lingual pressure during swallowing
Number of subjects: 20
Study 25812179 — intervention group
Group type: COMPARATOR
Intervention: Typical swallows
Number of subjects: 20
Study 23760668 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-specific biofeedback
Number of subjects: 31
Study 23760668 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific relaxation biofeedback
Number of subjects: 31
Study 23760668 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 31
Study 21907600 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg · day(‐1))
Number of subjects: 7
Study 21907600 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aspirin (650 mg · day(‐1))
Number of subjects: 7
Study 21907600 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose capsule)
Number of subjects: 7
Study 19184028 — intervention group
Group type: EXPERIMENTAL
Intervention: Raj yoga program (bi-weekly for 12 sessions)
Number of subjects: 47
Study 19184028 — intervention group
Group type: COMPARATOR
Intervention: Control group (no yoga)
Number of subjects: 47
Study 16982288 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 50 mg
Number of subjects: 150
Study 16982288 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 25 mg
Number of subjects: 150
Study 16982288 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (saline)
Number of subjects: 150
Study 15896619 — intervention group
Group type: EXPERIMENTAL
Intervention: Novare Enclose II manual proximal anastomotic device
Number of subjects: 30
Study 15896619 — intervention group
Group type: COMPARATOR
Intervention: Partial side clamp for proximal anastomoses
Number of subjects: 30
Study 11246309 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative weaning plan (CWP)
Number of subjects: 0
Study 11246309 — intervention group
Group type: COMPARATOR
Intervention: Control (historical controls)
Number of subjects: 0
Study 11327442 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus zalcitabine (200 mg zidovudine three times daily + 0.75 mg zalcitabine three times daily)
Number of subjects: 256
Study 11327442 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine monotherapy (200 mg three times daily)
Number of subjects: 256
Study 11327442 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus zalcitabine
Number of subjects: 256
Study 11327442 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine monotherapy
Number of subjects: 256
Study 8434265 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education message and antimalarial drug intervention 1
Number of subjects: 0
Study 8434265 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education message and antimalarial drug intervention 2
Number of subjects: 0
Study 8434265 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education message and antimalarial drug intervention 3
Number of subjects: 0
Study 8434265 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard malaria chemoprophylaxis program)
Number of subjects: 0
Study 3315267 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A - 8 mg/kg at 0700 hr and 4 mg/kg at 1900 hr
Number of subjects: 12
Study 3315267 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B - 6 mg/kg at 0700 hr and 6 mg/kg at 1900 hr
Number of subjects: 12
Study 3315267 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment C - 4 mg/kg at 0700 hr and 8 mg/kg at 1900 hr
Number of subjects: 12
Study 30917809 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching with 40% hydrogen peroxide for 2×45 min with a 1-week interval
Number of subjects: 48
Study 30917809 — intervention group
Group type: COMPARATOR
Intervention: Control group without bleaching treatment
Number of subjects: 48
Study 30917809 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermocycling (5000 cycles at 5°C and 55°C)
Number of subjects: 48
Study 30917809 — intervention group
Group type: EXPERIMENTAL
Intervention: No thermocycling
Number of subjects: 48
Study 28272596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists obtaining admission medication histories (AMHs)
Number of subjects: 2
Study 26100064 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 24485339 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sucrose solution
Number of subjects: 15
Study 24485339 — intervention group
Group type: COMPARATOR
Intervention: Aspartate solution
Number of subjects: 15
Study 24485339 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pure water)
Number of subjects: 15
Study 24485339 — intervention group
Group type: COMPARATOR
Intervention: Cortisol levels after all treatments (sucrose, aspartate, placebo)
Number of subjects: 15
Study 21480694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 105
Study 18992346 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9*3 allele
Number of subjects: 18
Study 18992346 — intervention group
Group type: COMPARATOR
Intervention: CYP2C9*1 and *2 alleles
Number of subjects: 18
Study 18992346 — intervention group
Group type: COMPARATOR
Intervention: CYP2C9*2 allele
Number of subjects: 18
Study 16487833 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide in high-risk group
Number of subjects: 2064
Study 16487833 — intervention group
Group type: COMPARATOR
Intervention: Placebo in high-risk group
Number of subjects: 2064
Study 16487833 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide in low-risk group
Number of subjects: 2064
Study 16487833 — intervention group
Group type: COMPARATOR
Intervention: Placebo in low-risk group
Number of subjects: 2064
Study 15486840 — intervention group
Group type: COMPARATOR
Intervention: Conventional report (Group A)
Number of subjects: 297
Study 15486840 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional report + written alert with clinical advice (Group B)
Number of subjects: 297
Study 15486840 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional report + written alert + oral clinical advice (Group C)
Number of subjects: 297
Study 11106526 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCON-T/N
Number of subjects: 30
Study 11106526 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 11106526 — intervention group
Group type: COMPARATOR
Intervention: ADCON-T/N and Control group
Number of subjects: 30
Study 9527321 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 50 mg/day
Number of subjects: 1828
Study 9527321 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene 20 mg/day
Number of subjects: 1828
Study 9527321 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol or beta-carotene supplementation
Number of subjects: 1828
Study 9527321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1828
Study 7931205 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced continuity of care
Number of subjects: 94
Study 7931205 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 94
Study 7931205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 7931205 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine blood levels above 123 ng/ml at week 2
Number of subjects: 94
Study 3203062 — intervention group
Group type: EXPERIMENTAL
Intervention: BN52063 (120 mg)
Number of subjects: 8
Study 3203062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3203062 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled PAF
Number of subjects: 8
Study 31591062 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal Artificial Intelligence Diagnostic System (GRAIDS)
Number of subjects: 84424
Study 31591062 — intervention group
Group type: EXPERIMENTAL
Intervention: GRAIDS
Number of subjects: 84424
Study 31591062 — intervention group
Group type: COMPARATOR
Intervention: Expert endoscopist
Number of subjects: 84424
Study 31591062 — intervention group
Group type: COMPARATOR
Intervention: Competent endoscopist
Number of subjects: 84424
Study 31591062 — intervention group
Group type: COMPARATOR
Intervention: Trainee endoscopist
Number of subjects: 84424
Study 28177741 — intervention group
Group type: EXPERIMENTAL
Intervention: 5:40 (24 × 5‐s efforts, 40‐s recovery)
Number of subjects: 9
Study 28177741 — intervention group
Group type: EXPERIMENTAL
Intervention: 15:120 (8 × 15‐s efforts, 120‐s recovery)
Number of subjects: 9
Study 28177741 — intervention group
Group type: COMPARATOR
Intervention: 30:240 (4 × 30‐s efforts, 240‐s recovery)
Number of subjects: 9
Study 25495716 — intervention group
Group type: EXPERIMENTAL
Intervention: Neg‐PTP
Number of subjects: 320
Study 25495716 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberation (for Neg‐PTP jurors)
Number of subjects: 320
Study 25495716 — intervention group
Group type: COMPARATOR
Intervention: No‐PTP
Number of subjects: 320
Study 25495716 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of ambiguous trial evidence
Number of subjects: 320
Study 23426738 — intervention group
Group type: EXPERIMENTAL
Intervention: Argus II system on
Number of subjects: 28
Study 23426738 — intervention group
Group type: COMPARATOR
Intervention: Argus II system off
Number of subjects: 28
Study 21837302 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilayer collagen matrix (CM)
Number of subjects: 5
Study 21837302 — intervention group
Group type: COMPARATOR
Intervention: Autogenous gingival graft (AGG)
Number of subjects: 5
Study 19040036 — intervention group
Group type: EXPERIMENTAL
Intervention: Healive (inactivated hepatitis A vaccine)
Number of subjects: 400
Study 19040036 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 400
Study 16930367 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐Hz rTMS of LTA
Number of subjects: 6
Study 16930367 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of LTA
Number of subjects: 6
Study 16930367 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 6
Study 16930367 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐Hz rTMS of mesial parietal cortex
Number of subjects: 6
Study 16930367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS of LTA
Number of subjects: 6
Study 16930367 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 6
Study 12569292 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotemustine plus whole brain irradiation (arm B)
Number of subjects: 76
Study 12569292 — intervention group
Group type: COMPARATOR
Intervention: Fotemustine alone (arm A)
Number of subjects: 76
Study 12866325 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aqueous (TAA AQ) 200 micrograms once daily (n = 75)
Number of subjects: 152
Study 12866325 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate aqueous (BDP) 336 micrograms twice daily (n = 77)
Number of subjects: 152
Study 10783825 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (2 g)
Number of subjects: 9
Study 10783825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8876516 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral group intervention
Number of subjects: 0
Study 1633125 — intervention group
Group type: EXPERIMENTAL
Intervention: Information sheet sent to clients regarding initial assessment sessions
Number of subjects: 0
Study 1633125 — intervention group
Group type: COMPARATOR
Intervention: No information sheet sent to clients (Control group)
Number of subjects: 0
Study 6743479 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg once‐daily)
Number of subjects: 0
Study 6743479 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg twice daily)
Number of subjects: 0
Study 6743479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3534594 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC)
Number of subjects: 796
Study 3534594 — intervention group
Group type: COMPARATOR
Intervention: BCG and postoperative irradiation
Number of subjects: 796
Study 3534594 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional chemotherapy with alternate drugs after completion of FAC
Number of subjects: 796
Study 31049783 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated Tobacco Product (THP)
Number of subjects: 280
Study 31049783 — intervention group
Group type: COMPARATOR
Intervention: Combustible Cigarette Smoking
Number of subjects: 280
Study 31049783 — intervention group
Group type: COMPARATOR
Intervention: Smoking Cessation
Number of subjects: 280
Study 31049783 — intervention group
Group type: COMPARATOR
Intervention: Never Smokers
Number of subjects: 280
Study 28985716 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 110
Study 28985716 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 110
Study 26637514 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m² as a two‐ to five‐minute i.v. infusion on days 1 and 8 of a 21‐day cycle
Number of subjects: 908
Study 24189290 — intervention group
Group type: EXPERIMENTAL
Intervention: CapOpus (motivational interviewing and cognitive behavior therapy)
Number of subjects: 103
Study 24189290 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 103
Study 21226785 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery plus text
Number of subjects: 80
Study 21226785 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery only
Number of subjects: 80
Study 21226785 — intervention group
Group type: EXPERIMENTAL
Intervention: Text only
Number of subjects: 80